Ascentage Pharma Group International (AAPG) Enterprise Value (2025 - 2026)

Ascentage Pharma Group International's Enterprise Value history runs 4 years deep, the most recent figure standing at -$348.3 million for Q4 2025.

• In Q4 2025, Enterprise Value fell 183.27% year-over-year to -$348.3 million; the TTM figure through Dec 2025 stood at -$348.3 million (down 183.27% YoY), while the FY2025 annual figure was -$343.7 million, down 179.52% from the prior year.
• Enterprise Value for Q4 2025 stood at -$348.3 million, down from -$231.9 million in the prior quarter.
• The five-year high for Enterprise Value was -$2.0 million in Q4 2023, with the low at -$348.3 million in Q4 2025.
• The 4-year median for Enterprise Value is -$189.2 million (2022), against an average of -$178.9 million.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value soared 98.95% in 2023, then plunged 6080.84% in 2024.
• Ascentage Pharma Group International's Enterprise Value stood at -$189.2 million in 2022, then jumped by 98.95% to -$2.0 million in 2023, then slumped by 6080.84% to -$122.9 million in 2024, then plunged by 183.27% to -$348.3 million in 2025.
• Business Quant data shows AAPG's Enterprise Value at -$348.3 million in Q4 2025, -$231.9 million in Q2 2025, and -$122.9 million in Q4 2024.